Only 31% of patients with prostate cancer receiving radiation therapy had a successful CT simulation on the first attempt, while more than half required multiple scans on the same day and nearly 17% ...
FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
New research in the February 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans ...
For years, prostate cancer specialists hit a wall when prostate-specific antigen (PSA) levels crept up after definitive treatment. The cancer was likely back — but where? And to what extent? Bone plus ...
More than 70% of patients with biochemically recurrent prostate cancer remained metastasis-free 5 years after PSMA PET/CT-guided salvage radiation therapy. Whole-pelvis radiation significantly ...
Prostate cancer is one of the most common cancers worldwide and remains a significant cause of cancer-related death. With increasing life expectancy, its incidence is projected to rise steadily in the ...
New research appearing in the Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to ...
The IAEA is launching a year-long coordinated research project to develop computed tomography-based guidelines on prostate cancer contouring — a critical step in the cancer treatment process that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results